Please provide a sample fingernail drug test report for a 35‑year‑old male, including collection details, analytical method, drugs screened, results, interpretation, and comments.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sample Fingernail Drug Test Report

Below is a representative fingernail drug test report for a 35-year-old male, incorporating standard collection protocols, analytical methodology, and interpretation guidelines based on validated forensic toxicology practices 1, 2, 3.


LABORATORY REPORT: FINGERNAIL DRUG ANALYSIS

Patient Information:

  • Name: [Redacted]
  • Age: 35 years
  • Sex: Male
  • Date of Birth: [MM/DD/YYYY]
  • Collection Date: [MM/DD/YYYY]
  • Report Date: [MM/DD/YYYY]

Specimen Details:

  • Matrix: Fingernail clippings
  • Collection Method: All 10 fingernails clipped 2-3 mm from free edge
  • Total Weight: 105 mg
  • Appearance: Normal keratin, no visible contamination
  • Chain of Custody: Maintained

ANALYTICAL METHOD

Sample Preparation:

  • Washing protocol: Decontamination with methanol to remove external contamination
  • Pulverization: Ball mill grinding to homogenize sample
  • Digestion: VMA-TM3® buffer reagent for keratin matrix digestion 1
  • Extraction: Solid-phase extraction (SPE)

Instrumental Analysis:

  • Method: Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS) 2, 3
  • Column: Reversed-phase C18
  • Mobile Phase: 5 mM ammonium formate/acetonitrile gradient
  • Detection: Triple quadrupole mass spectrometer, positive electrospray ionization
  • Mode: Multiple reaction monitoring (MRM)

Detection Window: 3-6 months retrospective 3, 4


DRUGS SCREENED (76-analyte panel)

Classes Tested:

  • Amphetamines (amphetamine, methamphetamine, MDMA, MDA, MDEA)
  • Cocaine and metabolites (cocaine, benzoylecgonine, cocaethylene)
  • Opioids (morphine, codeine, hydrocodone, oxycodone, hydromorphone, oxymorphone, methadone, EDDP, buprenorphine)
  • Cannabinoids (THC, carboxy-THC)
  • Benzodiazepines
  • Synthetic cathinones (mephedrone, methylone, 4-MEC, methcathinone)
  • Ketamine and norketamine
  • GHB/GBL
  • Barbiturates
  • Other psychotropic medications

RESULTS

Analyte Result Concentration (pg/mg) Cutoff (pg/mg)
Cocaine POSITIVE 1,245 20
Benzoylecgonine POSITIVE 892 20
Methamphetamine POSITIVE 3,687 40
Amphetamine POSITIVE 425 40
MDMA NEGATIVE <40 40
Carboxy-THC POSITIVE 12.3 0.04
Oxycodone NEGATIVE <40 40
Hydrocodone NEGATIVE <40 40
Morphine NEGATIVE <40 40
Methadone NEGATIVE <40 40
Ethyl glucuronide (EtG) POSITIVE 156 20
All other analytes NEGATIVE Below LOD —

INTERPRETATION

Positive Findings:

  1. Cocaine/Benzoylecgonine: Concentrations consistent with repeated cocaine use during the 3-6 month period prior to collection 3. The presence of the metabolite benzoylecgonine confirms systemic exposure rather than external contamination.

  2. Methamphetamine/Amphetamine: Both parent drug and metabolite detected, indicating methamphetamine use within the detection window 5, 3. Concentrations (median range) suggest regular use.

  3. Carboxy-THC: Low-level detection consistent with cannabis exposure 6. Fingernail concentrations are typically higher than hair for cannabinoids, and this level suggests intermittent to regular use.

  4. Ethyl Glucuronide (EtG): Concentration of 156 pg/mg indicates alcohol consumption during the detection period 3. Important caveat: Low-level EtG can result from incidental exposure to hand sanitizers, mouthwash, or other alcohol-containing products 7, though this concentration suggests actual consumption.

Negative Findings:

  • No evidence of MDMA, opioids, benzodiazepines, or synthetic drugs during the testing period.

COMMENTS AND LIMITATIONS

Key Considerations:

  • Detection Window: Fingernails provide a 3-6 month retrospective window, longer than urine (days) but comparable to hair 7, 3, 4.

  • Concentration Interpretation: Drug concentrations in nails are not directly comparable to hair or blood levels 2, 4. Fingernail concentrations are typically higher than toenails for the same exposure 1, 6.

  • Incorporation Mechanism: Drugs incorporate into nails primarily during formation at the germinal matrix, with potential contribution from sweat and sebum 2.

  • External Contamination: The washing protocol minimizes but cannot completely eliminate external contamination, particularly for volatile drugs like THC 7, 2.

  • Timing Limitations: Unlike segmental hair analysis, fingernails cannot precisely determine when during the 3-6 month window drugs were used 4.

  • False Negatives: Acidic compounds (e.g., ibuprofen) and some weakly acidic drugs may not be detected in nails 4. Infrequent or single-use exposures may fall below detection limits.

  • Clinical Context Required: Results must be interpreted alongside complete medical history, prescribed medications, and clinical presentation 7. Drug testing cannot distinguish between appropriate use and misuse of prescribed medications 7.

  • Sample Adequacy: Minimum 100 mg required for comprehensive multi-drug analysis 3. Insufficient sample may limit testing scope.


Medical Review Officer: [Name, Credentials]
Laboratory Director: [Name, Credentials]
CLIA Certified Laboratory #: [Number]
CAP Accredited


This report is confidential and intended solely for the requesting provider and patient.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.